Χώρα: Αυστραλία
Γλώσσα: Αγγλικά
Πηγή: Department of Health (Therapeutic Goods Administration)
bosentan monohydrate, Quantity: 129.082 mg
Alphapharm Pty Ltd
bosentan monohydrate
Tablet, film coated
Excipient Ingredients: povidone; glyceryl behenate; sodium lauryl sulfate; maize starch; sodium starch glycollate type A; magnesium stearate; pregelatinised maize starch; titanium dioxide; hypromellose; purified talc; triacetin; purified water; strong ammonia solution; ethylcellulose; oleic acid; medium chain triglycerides
Oral
60
(S4) Prescription Only Medicine
BOSENTAN VIATRIS is indicated for the treatment of,? idiopathic pulmonary arterial hypertension,? familial pulmonary arterial hypertension,? pulmonary arterial hypertension associated with scleroderma or,? pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts including Eisenmenger?s physiology ,in patients with WHO functional Class II, III or IV symptoms
Visual Identification: A white to off-white, film coated, oval, biconvex, beveled edge tablet debossed with 'M' on one side of the tablet and 'BN2' on the other side.; Container Type: Blister Pack; Container Material: PVC/PVDC/Al; Container Life Time: 36 Months; Container Temperature: Store below 25 degrees Celsius
Licence status A
2016-12-19
AUSTRALIAN PRODUCT INFORMATION BOSENTAN MYLAN _Bosentan (as monohydrate) film-coated tablet _ 1 NAME OF THE MEDICINE Bosentan (as monohydrate) _._ 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Bosentan monohydrate, a white to off-white powder, is practically insoluble at low pH (0.1 mg/100 mL at pH 1.1 and 4.0; 0.2 mg/100 mL at pH 5.0). Solubility increases at higher pH values (43 mg/100 mL at pH 7.5). In the solid state, bosentan monohydrate is very stable, is not hygroscopic and shows no light sensitivity. BOSENTAN MYLAN 62.5 mg film coated tablets each contain 64.5411 mg of bosentan monohydrate, equivalent to 62.5 mg of bosentan, as the active ingredient. BOSENTAN MYLAN 125 mg film-coated tablets each contain 129.082 mg of bosentan monohydrate, equivalent to 125 mg of bosentan, as the active ingredient. Excipients of Known effects: BOSENTAN MYLAN also contains traces of sulfites For the full list of excipients, see Section 6.1 LIST OF EXCIPIENTS. 3 PHARMACEUTICAL FORM BOSENTAN 62.5 mg white to off-white, film-coated, round, biconvex, beveled edge tablet debossed with “M” on one side of the tablet and “BN1” on the other side. BOSENTAN MYLAN 125 mg white to off-white, film-coated, oval, biconvex, beveled edge tablet debossed with “M” on one side of the tablet and “BN2” on the other side. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS BOSENTAN MYLAN is indicated for the treatment of idiopathic pulmonary arterial hypertension familial pulmonary arterial hypertension pulmonary arterial hypertension associated with scleroderma or pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts including Eisenmenger’s physiology in patients with WHO functional Class II, III or IV symptoms. 4.2 DOSE AND METHOD OF ADMINISTRATION BOSENTAN MYLAN may cause birth defects and is contraindicated in pregnancy. See SECTION 4.3 CONTRAINDICATIONS and SECTION 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE. Rare cases of hepatic cirrhosis and hepatic failure have been reporte Διαβάστε το πλήρες έγγραφο